fbpx
Stylish and compact, these new Canon instant printers make creative pursuits easyRead more Nigerian Law Enforcement agencies open investigations on Hawilti and company executives for criminal breach of trust, cheating, defrauding investors schemeRead more Famine looms in Somalia, but many ‘hunger hotspots’ are in deep troubleRead more Launch of the 3rd Edition of the Choiseul Africa Business Forum, a Must-Attend Event for the Business Community in Africa October 19th & 20th, 2022 in Casablanca, MoroccoRead more World’s Biggest Afrobeats Music Festival Afro Nation Extends Partnership with APO Group until 2025Read more Master Trainer (MT) National Meeting on Sustainable Coffee Practices Organized by The International Islamic Trade Finance Corporation in Collaboration with The Sustainable Coffee Platform of Indonesia (SCOPI)Read more Thai Ambassador met the Thai Community in Dar es Salaam and Zanzibar and visited the Buddhist Temple in TanzaniaRead more Generation Africa awards US$100,000 to two young agripreneurs from Kenya and Uganda in the fourth annual GoGettaz Agripreneur Prize Competition at the African Green Revolution Forum Summit in Kigali, RwandaRead more Medicaid Cancer Foundation and AstraZeneca celebrate Prostate Cancer Awareness month with the launch of Project Icon NigeriaRead more Eight Tokyo International Conference on African Development (TICAD8): President Barrow Discusses Inclusive Development in The Gambia with United Nations Development Programme (UNDP) Assistant AdministratorRead more

US begins clinical trial to test monkeypox vaccine

show caption
People line up to speak with healthcare workers with New York City Department of Health and Mental Hygiene at intake tents where individuals are registered to receive the monkeypox vaccine./AFP
Print Friendly and PDF

Sep 08, 2022 - 02:10 PM

WASHINGTON — US health authorities announced Thursday they would carry out a clinical trial to test different dosing strategies of the Jynneos monkeypox vaccine, amid uncertainty over its effectiveness.

The trial will enroll 200 adults aged 18-50 across the country, and is sponsored by the National Institute of Allergy and Infectious Diseases.

The Jynneos vaccine, manufactured by Denmark-based Bavarian Nordic, has been approved by the United States for the prevention of smallpox and monkeypox in people aged 18 and older.

But while the highest-risk group, men who have sex with men, are encouraged to get the vaccine, there is no clear picture of how well it works in real world settings.

The new trial isn’t designed to produce an efficacy estimate, but rather measure the immune response of different dosing levels and administration methods.

“NIAID’s trial of JYNNEOS will provide important information on the immunogenicity, safety, and tolerability of alternative dosing approaches that would expand the current supply of vaccine,” said NIAID director Anthony Fauci in a statement.

Among the participants, one group will be injected subcutaneously — that is, under the skin. The vaccine is based on attenuated virus that is modified so it can’t replicate, and is given in two doses 28 days apart.

A second group will receive their shots intradermally, meaning between the layers of the skin. This strategy is meant to expand the availability of vaccines because it uses one-fifth of the standard dose.

A third group will also receive their shots intradermally, but at half the dosing level of the second group.

Scientists will test the peak immune responses and compare the side effects across the groups.

President Joe Biden’s administration has bet heavily on the Jynneos vaccine to stem the spread of monkeypox, which has affected more than 20,000 people in the United States since May.

But the question of how well the shot prevents infection versus minimizing disease would require further study to answer.

The current global outbreak is primarily affecting gay and bisexual men.

Historically, the virus has been spread via direct contact with lesions, body fluids and respiratory droplets, and sometimes through indirect contamination via surfaces such as shared bedding.

But in this outbreak, there is preliminary evidence that sexual transmission may also play a role.

The virus causes painful skin lesions and flu-like symptoms.

Most people fully recover, but the disease can cause serious complications, including bacterial infections, brain inflammation and death.

MAORANDCITIES.COM uses both Facebook and Disqus comment systems to make it easier for you to contribute. We encourage all readers to share their views on our articles and blog posts. All comments should be relevant to the topic. By posting, you agree to our Privacy Policy. We are committed to maintaining a lively but civil forum for discussion, so we ask you to avoid personal attacks, name-calling, foul language or other inappropriate behavior. Please keep your comments relevant and respectful. By leaving the ‘Post to Facebook’ box selected – when using Facebook comment system – your comment will be published to your Facebook profile in addition to the space below. If you encounter a comment that is abusive, click the “X” in the upper right corner of the Facebook comment box to report spam or abuse. You can also email us.